Clinical trials: psoriasis
Chronic Plaque Psoriasis
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
- Trial name
- VALUE (NCT03982394)
- Where
- 302 sites in Argentina, Australia and 19 more
- Volunteers
- 2,759 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- FUTURE 4 (NCT02294227)
- Testing
- Secukinumab
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
This is a long-term, randomized, multi-center, open-label study of infliximab treatment in adults with moderate to severe plaque-type psoriasis.
- Trial name
- NCT00358670
- Testing
- infliximab
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy
To evaluate whether a short-term course of methotrexate in patients treated with efalizumab (Raptiva) increases efficacy. The secondary objectives of this study are 1) to evaluate the efficacy of Raptiva in maintaining the…
- Trial name
- NCT00368654
- Testing
- Methotrexate, Raptiva
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Psoriasis
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque…
- Trial name
- NCT02564042
- Testing
- GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
- Where
- 46 sites in United States, Canada and 1 more
- Volunteers
- 227 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis, Crohn's Disease
Predicting Medication Response for Autoimmune Disease
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients.
- Conditions
- Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
- Trial name
- REEF (NCT04995783)
- Testing
- Coral FRS test
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Coral Genomics, Inc.
Psoriatic Arthritis, Psoriasis
Ultrasound Enthesitis Response in Psoriatic Arthritis
The aim of this observational study will be to recruit 100 Psoriatic Arthritis (PsA) patients beginning on their biologic therapy and asses, both clinically and with the use of ultrasound (US), how enthesitis responds to biologic…
- Conditions
- Psoriatic Arthritis, Psoriasis, Enthesitis
- Trial name
- NCT03955861
- Testing
- adalimumab, Certolizumab, Etanercept
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Belfast Health and Social Care Trust
Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic…
- Trial name
- NCT03025542
- Testing
- Bimekizumab
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07532486
- Testing
- Guselkumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Psoriasis
CP-690-550 Ointment For Chronic Plaque Psoriasis
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
- Trial name
- NCT01246583
- Testing
- CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- Pfizer
Atopic Dermatitis, Psoriasis
Evaluating Treatment Resistant Dermatitis TaroIIR
Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices.
- Trial name
- NCT03050294
- Testing
- Phone calls, Desoximetasone 0.25% spray
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Fingernail Psoriasis
Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis
The purpose of this clinical study is to compare the efficacy and safety of three concentrations of topical methotrexate for the treatment of fingernail psoriasis.
- Trial name
- NCT00666354
- Testing
- Methotrexate
- Where
- 7 sites in United Kingdom
- Volunteers
- 83 people
- Sponsor
- MediQuest Therapeutics
Psoriasis
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
- Trial name
- HPA axis (NCT02131324)
- Testing
- DFD06 Cream, Clobetasol Propionate Cream 0.05%
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Promius Pharma, LLC
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
There is clearly a need for further data on the efficacy of biologic agents in the treatment of nail and scalp psoriasis, especially in the routine clinical setting.
- Trial name
- NCT01202565
- Where
- 73 sites in Czechia, Estonia and 6 more
- Volunteers
- 506 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
This study will evaluate the safety and efficacy of brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with interleukin (IL)-17A therapies.
- Trial name
- NCT03403036
- Testing
- Brodalumab
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Plaque Psoriasis
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment [IGA] score of 3 or 4).
- Trial name
- NCT02514577
- Testing
- IDP-122 Lotion, IDP-122 Vehicle Lotion
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Bausch Health Americas, Inc.
Periodontal Diseases
The Effect of Periodontal Treatment on Psoriasis
There is a relationship between psoriasis and periodontal disease. This relationship may be double-sided.
- Trial name
- NCT03939936
- Testing
- Psoriatic measurements, Non-surgical periodontal treatment, saliva samples
- Where
- Turkey (Türkiye)
- Volunteers
- 92 people
- Sponsor
- Ozge Gokturk
Arthritic Psoriasis
Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)
Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks.
- Trial name
- NCT07706530
- Testing
- CBP-0276 capsules 100mg
- Where
- Mexico
- Volunteers
- 240 people
- Sponsor
- Clarent Biopharma, Inc.
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
The VIP-U Study is a clinical trial designed to investigate the effect of ustekinumab (Stelara) and placebo on reducing vascular inflammation and cardiometabolic risk biomarkers in patients with moderate to severe psoriasis.
- Trial name
- VIP-U (NCT02187172)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Pennsylvania
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.